Roche announced that its Elecsys Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in patients diagnosed with relapsing remitting multiple sclerosis (RRMS). The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods.
By providing deeper insight into underlying neuroinflammatory activity, Elecsys NfL has the potential to enable effective MS monitoring and earlier clinical intervention. The test brings meaningful innovation to MS disease management, offering clinicians a minimally invasive way to monitor the biological damage caused by multiple sclerosis. Using a simple blood test to measure NfL ?
a protein released during nerve cell injury ? Elecsys NfL provides a picture of the neuroinflammation associated with multiple sclerosis, and could help to make more regular monitoring a reality for more people living with the disease. Early and regular monitoring of disease activity is critical to optimising treatment, yet some patients can find it difficult to access routine assessments such as MRI scanning that would allow timely detection of changes in their condition.
The Elecsys NfL test provides a different type of insight by measuring biological markers of neuroaxonal damage that reflect neuroinflammation. These insights complement routine clinical assessments and MRI, potentially aiding in earlier and better-informed clinical management. Performed on Roche?s widely available cobas instruments, the Elecsys NfL test provides standardised and consistent results, ensuring reliable insights regardless of where the test is carried out.
Requiring only a simple blood sample, collections can be done locally, reducing the need for patients to travel to specialist centres. With traditional testing for multiple sclerosis often limited by geographic, financial, or logistical barriers, Elecsys NfL makes frequent monitoring more practical and accessible. Neurofilament Light Chain (NfL) is an abundant cytoskeletal protein found almost exclusively in neurons and is a sensitive indicator of neuroaxonal damage.
Under normal conditions, NfL is released at low levels from axons; however, release increases with age and following neuroaxonal damage. Consequently, abnormally elevated NfL concentrations can be measured in cerebrospinal fluid and blood in a range of acute and chronic neurological disorders. Roche?s Elecsys NfL is an in vitro quantitative immunoassay for the measurement of NfL protein in human serum and plasma.
Elecsys NfL is intended to be used to reflect neuroinflammation in adult subjects diagnosed with relapsing-remitting multiple sclerosis. The test was granted Breakthrough Device Designation by the US FDA in November 2023. Following CE Mark approval, broad access to testing will exist through the large number of instruments currently available in countries accepting CE mark.
